228 related articles for article (PubMed ID: 12034365)
1. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.
Willmore E; Errington F; Tilby MJ; Austin CA
Biochem Pharmacol; 2002 May; 63(10):1807-15. PubMed ID: 12034365
[TBL] [Abstract][Full Text] [Related]
2. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
[TBL] [Abstract][Full Text] [Related]
3. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
4. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique.
Willmore E; Frank AJ; Padget K; Tilby MJ; Austin CA
Mol Pharmacol; 1998 Jul; 54(1):78-85. PubMed ID: 9658192
[TBL] [Abstract][Full Text] [Related]
5. Camptothecin-stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay (trapped in agarose DNA immunostaining).
Padget K; Carr R; Pearson AD; Tilby MJ; Austin CA
Biochem Pharmacol; 2000 Mar; 59(6):629-38. PubMed ID: 10677579
[TBL] [Abstract][Full Text] [Related]
6. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II-mediated alterations of K562 drug resistant sublines.
Zhou R; Wang Y; Gruber A; Larsson R; Castaños-Vèlez E; Liliemark E
Med Oncol; 1999 Sep; 16(3):191-8. PubMed ID: 10523799
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
Leukemia; 1996 Jul; 10 Suppl 3():S46-S49. PubMed ID: 8656700
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
Leukemia; 1996 Jul; 10(7):1177-80. PubMed ID: 8683999
[TBL] [Abstract][Full Text] [Related]
11. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
13. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
[TBL] [Abstract][Full Text] [Related]
15. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
17. Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Elliott SL; Austin CA
Int J Cancer; 2008 Nov; 123(9):2217-21. PubMed ID: 18712718
[TBL] [Abstract][Full Text] [Related]
18. Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells.
Locke VL; Davey RA; Davey MW
Br J Haematol; 1999 Jul; 106(1):86-91. PubMed ID: 10444167
[TBL] [Abstract][Full Text] [Related]
19. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Fukushima T; Yamashita T; Yoshio N; Misaki H; Yamauchi T; Imamura S; Urasaki Y; Ueda T
Leuk Res; 1999 Jan; 23(1):37-42. PubMed ID: 9933133
[TBL] [Abstract][Full Text] [Related]
20. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
